Quris-AI News
20 articles
Pharma giant Merck expands collaboration with Quris-AI | CTech
Israeli startup Quris-AI, which develops AI solutions for the pharmaceutical industry, has extended its collaboration with Merck KGaA. The partnership follows a successful preclinical study assessing Quris-AIs ability to predict drug toxicity. Merck will now further leverage Quris-AIs platform to identify liver toxicity risks in drug candidates. Merck has the option to obtain up to a five-year exclusive license to a specific disease domain, which could result in a substantial payment to Quris-AI. The startup recently raised $37 million in seed funding, with an additional $9 million led by SoftBank Vision Fund 2.
PartnersInvestment
Quris-AI was featured in a 7 min episode of “Inside the Blueprint” TV show on Bloomberg and Fox Business!
ד״ר צחון בנטוויץ׳ - הבינה המלאכותית שתבטל ניסויים בבעלי חיים
Dr. Tzachon Ben-Tovitch, a doctor who has worked in the healthcare field for a short time, founded his first company in the healthcare industry. With several successful exits, including the IPO of Rosetta Genomics, he founded CureAI, a company that aims to significantly reduce the time, cost, and suffering involved in clinical trials of new drugs using artificial intelligence. CureAI recently raised $37 million in funding led by SoftBank. The company has a unique technology and the potential to not only provide a good return for investors but also save lives.
InvestmentPartners
Podcast: AI, Chips and Drug Discovery - with Isaac Bentwich, Emir Mustafa Isler and Priya Dialani
The Delta Dialog Podcast is hosting a Content Partner segment where they discuss AI and technology, its developments and usage in different sectors and industries, and how it changes the world. The program features conversations with leading experts in the field of AI, Data Science, and healthcare, discussing how these technologies can and will impact everyday life.
Partners
Quris-AI: an artificial intelligence innovator disrupting the drug development process
Quris-AI, an AI innovator, is developing a Bio-AI Clinical Prediction Platform to address the problem of predicting the clinical safety of drug candidates. The platform integrates high-throughput three-dimensional (3D) and multi-organ technologies, real-time sensing, and stem-cell genomic diversity with state-of-the-art machine learning. By using a 3D multi-organ approach, Quris aims to improve the predictability of drug safety by replicating the systemic effects of drugs in interconnected miniaturized human organs. The platform also incorporates AI to analyze the massive amounts of data generated and predict drug safety in humans. Quris is currently collaborating with Merck KGaA and is seeking partnerships with other pharmaceutical companies. The company has received $37 million in seed funding and is led by a team of experts in various fields.
InvestmentPartners
Quris-AI Named to Fast Company's Annual List of the World's Most Innovative Companies for 2023
Quris-AI has been named one of Fast Companys Most Innovative Companies for 2023. The company is leveraging AI to disrupt the drug development process and tailor drugs to individual patients needs. Quris has fast-tracked its drug R&D, expanded its team, and established partnerships. Notable highlights include a multi-year agreement with Merck KGaA for clinical safety prediction testing and securing an additional $9 million in seed funding. Quris is also working with The New York Stem Cell Foundation Research Institute to train its AI platform. Fast Companys Most Innovative Companies issue will be available in March/April 2023.
PartnersInvestment
פלטפורמת חיזוי מבוססת AI של חברת Quris מובילה מהפכה בתהליכי פיתוח התרופות
Israeli start-up Quris is using artificial intelligence (AI) to revolutionise the pharmaceutical industry. The company has developed a platform that uses AI to predict the safety of new drugs, replacing traditional animal testing. The technology has the potential to save pharmaceutical companies billions of dollars and significantly reduce the time it takes to develop a new drug. Quris has already secured a partnership with pharmaceutical giant Merck and is in talks with other leading drug companies. The company has raised $37 million in seed funding and is currently in the process of raising $100 million in a Series A round.
InvestmentPartners
האם מתקרב סוף עידן הניסויים בבעלי חיים בפיתוח תרופות?
The article discusses a recent change in US legislation that allows the FDA to approve new drugs without animal testing. This change is expected to have a negative impact on pharmaceutical companies, as failed clinical trials have already cost them over $36 billion in 2020. The article highlights the potential for even greater losses in the coming decade, estimated at half a trillion dollars. The new law aims to streamline the drug approval process but raises concerns about the effectiveness and safety of drugs that have not been tested on animals. The article does not mention any specific partners, customers, or financial details.
CustomersPartners
Quris-AI and MBZUAI to launch world-class Bio-AI center in Abu-Dhabi
Abu Dhabi-based collaboration between Quris-AI and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) to develop a world-class Bio-AI center in Abu Dhabi. The collaboration aims to accelerate the development of personalized medications using AI. Quris-AI is establishing its subsidiary, Quris-UAE, in Abu Dhabi as part of the collaboration. The collaboration will focus on targeted drug development, reducing failure rates in clinical trials, and eliminating the need for animal testing. The collaboration is aligned with the UAEs vision to become a center of excellence in AI. The collaboration will also involve research projects and the development of personalized drug administration protocols. MBZUAI will contribute its expertise in AI and computational biology to enhance Quris efforts.
PartnersInvestment
Quris prepping to raise as much as $100 million in Series A capital for clinical trial tech
AI innovator Quris seed funding grows to $37 million
Quris, an AI innovator in the pharmaceutical arena, has secured an additional $9 million in seed funding, bringing its total seed round funding to $37 million. Led by SoftBank Vision Fund 2 and other investors, the funding will help Quris advance its Bio-AI platform, expand its team and collaborations, and accelerate its drug research. Quris is developing a Bio-AI clinical-prediction platform that simulates clinical trials using stem-cell-derived tissue and AI, aiming to replace animal testing and reduce the failure rate of drug candidates in clinical trials. The partnership with Merck KGaA to pilot Quris Bio-AI safety prediction platform is also mentioned.
InvestmentPartners
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products
SoftBank leads $9 million investment in AI pharma startup Quris | CTech
Israeli AI startup Quris has secured an additional $9 million in Seed funding, bringing its total Seed round funding to $37 million. The funding, led by SoftBank Vision Fund 2, will help Quris advance its Bio-AI platform, grow its team, and speed up its drug research. This investment marks SoftBanks first investment in an Israeli company in months. Quris has also signed a cooperation agreement with German pharma giant Merck, allowing Merck to use Quris platform for testing drugs and identifying safe options. The agreement could potentially yield Quris tens of millions of dollars. Quris was founded by CEO Isaac Bentwich and CTO Yossi Haran and currently employs around 40 people.
InvestmentPartners
Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction
Quris Technologies has been recognized with the 2022 Europe Technology Innovation Leadership Award for its Quris Bio-AI Clinical Prediction Platform. The platform uses artificial intelligence to predict the safety and efficacy of new drugs, enhancing the drug development process. It is able to accurately predict which drug candidates will work safely in humans, reducing the costs of failed clinical trials for pharmaceutical companies. Quris stands out from competitors due to its commitment to innovation and creativity, as well as its drug pipeline and personalized medicine services. The company has a strong intellectual property portfolio and is preparing for clinical testing of its first AI-based Fragile-X drug. The recognition from Frost & Sullivan validates Quris mission to revolutionize drug development and remove barriers in the pharma industry.
Customers
Quris and Bio-AI Drug Development (Pt. 1) - Patient Worthy
The article discusses Quris Technologies Ltd., an AI pharmaceutical company focused on drug safety prediction and personalized drug development. The company aims to revolutionize the drug development process using its proprietary Bio-AI Clinical Prediction Platform. Quris has signed collaborations with Merck KGaA and the New York Stem Cell Foundation, and additional partnerships are expected in the future. The platform utilizes Patients-on-a-Chip technology to create miniature organs for testing thousands of drugs, genomic diversity to test therapies on different cells and organs, and artificial intelligence and machine learning to personalize drug selection based on genetic markers. The article highlights the potential of Quris to improve drug development outcomes and reduce costs. The impact on the company is growth-positive, as it is working towards revolutionizing drug development and safety.
Partners
Pharma giant Merck inks deal with Israel's Quris for clinical safety prediction
Israeli company Quris has signed a cooperation agreement with German pharma giant Merck to use Quris predictive technology based on artificial intelligence to test drugs. The exclusive agreement is for a period of five years and is estimated to yield Quris tens of millions of dollars. Merck will gain access to Quris forecasting platform and will be able to identify safe drugs to use. Quris platform combines miniaturized human tissues on chips, nanosensors, and AI to predict the effectiveness and safety of drugs in the human body. The collaboration aims to improve the drug development process and reduce the reliance on animal testing. Quris recently raised $28 million in a seed funding round led by Welltech Ventures, iAngels, and GlenRock Capital.
PartnersInvestment
Quris closes record $28 million Seed funding for AI drug development platform
Israeli startup Quris has raised $28 million in Seed funding, a record for Seed funding in Israel. The company uses AI-powered miniaturized patients-on-a-chip to accelerate the development of drugs and predict their safety for humans. Quris aims to eliminate the risks and costs of failed clinical trials and reduce reliance on ineffective animal testing. The funding will be used to test hundreds and thousands of drugs with Quris chip to create data on how the human body responds to these drugs. Quris plans to partner with pharmaceutical companies and develop its own drugs. The company is focused on expanding industry collaborations and preparing its first drug for clinical testing in 2022. Quris was founded by Isaac Bentwich and Yossi Haran and currently employs around 20 people in Tel Aviv and Boston.
InvestmentExpand
בדיקת תרופות על צ'יפים במקום על בני אדם: הסטארטאפ החדש של זוכה הנובל הישראלי
Israeli startup Quris, co-founded by Dr. Tzach Ben-Knaz and Yossi Hermon in 2019, is developing a platform that uses Patients-on-a-Chip to test the safety and efficacy of drugs. The platform uses nano-sensors to examine the effects of each drug or vaccine on the patient and tags them in the companys AI system. Quris has reported that its platform has been used to develop a drug for Brittle X syndrome, which is expected to enter clinical trials in 2022. The company has 18 patents approved or in the approval process and has signed partnerships with Israeli universities and the New York Stem Cell Research Institute (NYSCF).
InvestmentPartners
Quris combines AI with 'patient on a chip' to speed drug development and reduce animal testing
Quris, a company that combines AI with data from a patient on a chip to provide robust drug testing without the need for animal testing, has raised a $9 million seed round. The company aims to build a small-scale simulation of a human body using organs-on-a-chip systems, which have been shown to be effective in simulating human organ responses to drugs. Quris uses a chip-on-chip technique that is smaller and more efficient than existing lab systems. The company also emphasizes the use of AI to interpret the data and drive unique insights. The funding will be used to further develop the technology and train the AI.
Investment
Quris combines AI with 'patient on a chip' to speed drug development and reduce animal testing
Quris, an Israel-based company, has raised a $9 million seed round to develop an AI-driven drug testing system that uses data from a patient on a chip to simulate human responses to drugs. The company aims to provide a cost-effective and accurate alternative to animal testing in drug discovery. Quriss approach builds on the concept of organs on a chip and combines it with AI technology. The company has received backing from prominent investors and advisors, including Welltech Ventures, iAngels, GlenRock Capital, and Softbank. The AI system developed by Quris can interpret data from multiple organ-on-a-chip systems, allowing for more efficient and reliable drug testing. The company plans to offer its services to pharmaceutical companies and develop its own drugs, starting with a treatment for Fragile X syndrome.
Investment
